Effect of interferon on the health-related quality of life of multiple myeloma patients: Results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + α-interferon

British Journal of Haematology

Volumn 94, Issue 2, 1996, Pages 324-332

  Wisløff, Finn ^a   Hjorth, Martin ^b   Kaasa, Stein ^c,d   Westin, Jan ^e  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b Lidkoping Hospital   (Sweden)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^d EORTC Study Group on Quality of Life   (Netherlands)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

interferon; multiple myeloma; plateau phase; quality of life; questionnaire

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; MELPHALAN; PREDNISONE; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ANOREXIA; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRY SKIN; FATIGUE; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NAUSEA; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VERTIGO; VOMITING; ARTHRALGIA; COGNITION; COUGHING; DISEASE FREE SURVIVAL; DIZZINESS; DRUG DOSE SEQUENCE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EMOTIONALITY; HAIR LOSS; HEADACHE; INTENTION TO TREAT ANALYSIS; MYALGIA; NIGHT SWEAT; PHASE 3 CLINICAL TRIAL; PHYSICAL ACTIVITY; SOCIAL INTERACTION; SORE THROAT; TREATMENT DURATION;

EID: 0029883430     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.d01-1802.x     Document Type: Article

References (21)

1. Aaronson, N.K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N.J., Filiberti, A., Flechtner, S., Fleishman, S.B., de Haes, J.C.J.M., Kaasa, S., Klee, M., Osoba, D., Razavi, D., Rofe, P.B., Schraub, S., Sneeuw, K., Sullivan, M. & Takeda, F. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85, 365-376.
2. Adams, F., Quesada, J.R. & Gutterman, J.U. (1984) Neuropsychiatric manifestations of human leukocyte Interferon therapy in patients with cancer. Journal of the American Medical Association, 252, 938-941.
3. Browman, G.P., Bergsagel, D., Sichert, D., O'Reilly, S., Wilson, K.S., Rubin, S., Belch, A., Shustik, C., Barr, R., Walker, I., James, K., Zee, B. & Johnston, D. (1995) Randomized trial of Interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada clinical trials group. Journal of Clinical Oncology, 13, 2354-2360.
4. Coates, A., Gebski, V., Bishop, J.F., Jeal, P.N., Woods, R.L., Snyder, R., Tattersall, M.H.N., Byrne, M., Harvey, V., Gill, G., Simpson, J., Drummond, R., Browne, J., van Cooten, R. & Forbes, J.F. (1987) Improving the quality of life during chemotherapy for advanced breast cancer. New England Journal of Medicine, 317, 1490-1495.
5. Cooper, M.R., Dear, K., McIntyre, O.R., Ozer, H., Ellerton, J., Canellos, G., Bernhardt, B., Duggan, D., Faragher, D. & Schiffer, C. (1993) A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. Journal of Clinical Oncology, 11, 155-160.
6. Cunningham, D., Powles, R., Viner, C., Meldrum, M., Gore, M., Selby, P. & Malpas, J. (1993) High dose chemotherapy and autologous bone marrow transplantation in multiple myeloma. IV International Workshop on Multiple Myeloma, Rochester, Minnesota, p. 102.
7. Earl, H.M., Rudd, R.M., Spiro, S.G., Ash, C.M., James, L.E., Law, C.S., Tobias, J.S., Harper, P.G., Geddes, D.M., Eraut, D., Partridge, M.R. & Souhami, R.L. (1991) A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. British Journal of Cancer. 64, 566-572.
8. Fayers, P.M., Aaronson, N.K., Bjordal, K. & Sullivan, M. (1995) EORTC QLQ-C30 Scoring Manual. EORTC Study Group on Quality of Life, Brussels.
9. Fayers, P.M., Bleehen, N.M., Girling, D.J. & Stephens, R.J. (1991) Assessment of quality of life in small-cell lung cancer using a daily diary card developed by the Medical Research Council Lung Cancer Working Party. British Journal of Cancer, 64, 299-306.
10. Hjermstad, M.J., Fosså, S.D., Bjordal, K. & Kaasa, S. (1995) Test/retest study of the European Organization for Research and Treatment of Cancer core quality-of-life questionnaire. Journal of Clinical Oncology, 13, 1249-1254.
11. Hopwood, P., Stephens, R.J. & Machin, D. (1994) Approaches to the analysis of quality of life data: experiences gained from a Medical Research Council lung cancer working party palliative chemotherapy trial. Quality of Life Research, 3, 339-352.
12. Kaasa, S., Bjordal, K., Aaronson, N., Moum, T., Wist, E., Hagen, S., Kvikstad, A., and The EORTC Study Group on Quality of Life (1995) The EORTC core quality of life questionnaire, (QLQ-C30): validity and reliability when analyzed with patients treated with palliative radiotherapy. European Journal of Cancer, 31A, 2260-2263.
13. Ludwig, H., Cohen, A.M., Polliack, A., Huber, H., Nachbaur, D., Senn, H.-J., Morant, R., Eckhardt, S., Günczler, P., Seewann, H.L., Schüller, J., Rhyner, K., Cavalli, F. & Fritz, E. (1995) Interferon-alpha for induction and maintenance treatment in multiple myeloma: results of two multicenter randomized trials. Annals of Oncology, 6, 467-476.
14. Mandelli, P., Avvisati, G., Amadori, S., Boccadoro, M., Gernone, A., Lauta, V.M., Marmont, F., Petrucci, M.T., Tribalto, M., Vegna, M.L., Dammacco, F. & Pileri, A. (1990) Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. New England Journal of Medicine, 322, 1430-1434.
15. α2) or high-dose cyclophosphamide to VBMCP to treat multiple myeloma: results from an ECOG phase III trial. Blood, 86, (Suppl. 1), 441a.
16. Österborg, A., Björkholm, M., Björeman, M., Brenning, G., Carlson, K., Celsing, F., Gahrton, G., Grimfors, G., Gyllenhammar, H., Hast, R., Johansson, B., Juliusson, G., Järnmark, M., Kimby, E., Lerner, R., Linder, O., Merk, K., Nilsson, B., Ohrling, M., Paul, C., Simonsson, B., Smedmyr, B., Svedmyr, E., Stalfelt, A-M., Strander, H., Udén, A-M., Ôsby, E. & Mellstedt, H. (1993) Natural interferon-α in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the myeloma group of central Sweden. Blood, 81, 1428-1434.
17. Renault, P.F. & Hoofnagle, J.H. (1989) Side-effects of alpha interferon. Seminars in Liver Disease, 9, 273-277.
18. Salmon, S.E., Crowley, J.J., Gragan, T.M., Finley, P., Pugh, R. & Barlogie, B. (1994) Combination chemotherapy, glucocorticoids. and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. Journal of Clinical Oncology, 12, 2405-2414.
19. The Nordic Myeloma Study Group (NMSG) (1996) Interferon-alfa-2b added to melphalan-prednisone for initial and maintenance treatment in multiple myeloma: a randomized, controlled trial. Annals of Internal Medicine, 124, 212-222.
20. Westin, J., Rödjer, S., Turesson, I., Cortelezzi, A., Hjorth, M. & Zador, G. (1995) Interferon alpha-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study, British Journal of Haematology. 89, 561-568.
21. Wisloff, F., Eika, S., Hippe, R. Hjorth, M., Holmberg, E., Kaasa, S., Palva, I. & Westin, J. (1996) Measurement of health-related quality of life in multiple myeloma. British Journal of Haematology, 92, 604-613.